鲁索利替尼治疗下真性红细胞增多症患者的播散性芽生菌病。
Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib.
机构信息
Department of Pharmacy, Tampa General Hospital, Tampa, Florida, USA.
Department of Pharmacy, University of California San Francisco, San Francisco, California, USA.
出版信息
BMJ Case Rep. 2021 Nov 1;14(11):e243694. doi: 10.1136/bcr-2021-243694.
Abstract
Ruxolitinib (RUX) is a kinase inhibitor used in the treatment of various medical conditions and its mechanism of action involves suppression of the immune system. While beneficial in treatment of polycythemia vera, myelofibrosis and other indications, it can also increase a patient's susceptibility to various infections, including bacterial, viral and fungal. We present a case of a patient being treated with RUX who presented with a disseminated fungal infection. This case emphasises the need for vigilance of endemic fungal infections in individuals who are on RUX therapy.
摘要
芦可替尼（RUX）是一种激酶抑制剂，用于治疗各种医疗状况，其作用机制涉及抑制免疫系统。虽然在治疗真性红细胞增多症、骨髓纤维化和其他适应症方面有益，但它也会增加患者对各种感染的易感性，包括细菌、病毒和真菌。我们报告了一例接受 RUX 治疗的患者出现播散性真菌感染的病例。该病例强调了在接受 RUX 治疗的个体中，需要警惕地方性真菌感染。
相似文献
1
Disseminated blastomycosis in a patient with polycythemia vera on ruxolitinib.鲁索利替尼治疗下真性红细胞增多症患者的播散性芽生菌病。
BMJ Case Rep. 2021 Nov 1;14(11):e243694. doi: 10.1136/bcr-2021-243694.
2
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies.芦可替尼治疗的真性红细胞增多症患者及其继发恶性肿瘤风险。
Ann Hematol. 2021 Nov;100(11):2707-2716. doi: 10.1007/s00277-021-04647-0. Epub 2021 Aug 31.
3
The impact of ruxolitinib on thrombosis in patients with polycythemia vera and myelofibrosis: a meta-analysis.鲁索替尼对真性红细胞增多症和骨髓纤维化患者血栓形成的影响：一项荟萃分析。
Blood Coagul Fibrinolysis. 2016 Sep;27(6):648-52. doi: 10.1097/MBC.0000000000000446.
4
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study.原发性骨髓纤维化和真性红细胞增多症后/或原发性血小板增多症后骨髓纤维化患者接受芦可替尼治疗的临床表现、结局和预后模型的差异。一项大型多中心研究中 MYSEC-PM 的新视角。
Semin Hematol. 2018 Oct;55(4):248-255. doi: 10.1053/j.seminhematol.2018.05.013. Epub 2018 Jun 5.
5
Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea.羟基脲耐药/不耐受的真性红细胞增多症患者接受芦可替尼或最佳可用疗法治疗后的主要临床结局的真实世界分析。
Cancer. 2022 Jul 1;128(13):2441-2448. doi: 10.1002/cncr.34195. Epub 2022 Apr 13.
6
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the "RAMP" Italian multicenter prospective study.芦可替尼在骨髓纤维化和真性红细胞增多症中的依从性：“RAMP”意大利多中心前瞻性研究。
Ann Hematol. 2024 Jun;103(6):1931-1940. doi: 10.1007/s00277-024-05704-0. Epub 2024 Mar 13.
7
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.克服骨髓纤维化和真性红细胞增多症的治疗挑战：芦可替尼的作用
Cancer Chemother Pharmacol. 2016 Jun;77(6):1125-42. doi: 10.1007/s00280-016-3012-z. Epub 2016 Mar 26.
8
A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis.一项关于芦可替尼与真性红细胞增多症和骨髓纤维化患者非黑色素瘤皮肤癌相关性的10年回顾性队列研究。
J Am Acad Dermatol. 2022 Feb;86(2):339-344. doi: 10.1016/j.jaad.2021.10.004. Epub 2021 Oct 11.
9
Imatinib and ruxolitinib association: first experience in two patients.伊马替尼与芦可替尼联合应用：两例患者的首次经验
Haematologica. 2014 Jun;99(6):e76-7. doi: 10.3324/haematol.2013.102525. Epub 2014 Mar 14.
10
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.芦可替尼与干扰素-α2 联合治疗真性红细胞增多症或骨髓纤维化患者：一项 II 期研究。
Haematologica. 2020 Sep 1;105(9):2262-2272. doi: 10.3324/haematol.2019.235648.
引用本文的文献
1
Disseminated Histoplasmosis in a Patient with Myelofibrosis on Ruxolitinib: A Case Report and Review of the Literature on Ruxolitinib-Associated Invasive Fungal Infections.鲁索替尼治疗的骨髓纤维化患者发生播散性组织胞浆菌病：一例报告及鲁索替尼相关侵袭性真菌感染的文献综述
J Fungi (Basel). 2024 Mar 31;10(4):264. doi: 10.3390/jof10040264.
本文引用的文献
1
Ruxolitinib-Associated Infections in Polycythemia Vera: Review of the Literature, Clinical Significance, and Recommendations.鲁索替尼相关的真性红细胞增多症感染：文献综述、临床意义及建议
Cancers (Basel). 2020 Oct 26;12(11):3132. doi: 10.3390/cancers12113132.
2
Coccidioidomycosis in Patients Treated With Ruxolitinib.接受鲁索替尼治疗患者的球孢子菌病
Open Forum Infect Dis. 2020 May 19;7(6):ofaa167. doi: 10.1093/ofid/ofaa167. eCollection 2020 Jun.
3
Fungal Infections with Ibrutinib and Other Small-Molecule Kinase Inhibitors.依鲁替尼及其他小分子激酶抑制剂引发的真菌感染
Curr Fungal Infect Rep. 2019 Sep;13(3):86-98. doi: 10.1007/s12281-019-00343-9. Epub 2019 Jul 5.
4
How I treat polycythemia vera.我如何治疗真性红细胞增多症。
Blood. 2019 Jul 25;134(4):341-352. doi: 10.1182/blood.2018834044. Epub 2019 May 31.
5
Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL).血液学和肿瘤学中免疫治疗和分子靶向药物相关感染。欧洲白血病感染会议（ECIL）立场文件。
Leukemia. 2019 Apr;33(4):844-862. doi: 10.1038/s41375-019-0388-x. Epub 2019 Jan 30.
6
Cutaneous, Intranasal Blastomycosis Infection in Two Patients from Southern West Virginia: Diagnostic Dilemma.西弗吉尼亚州南部两名患者的皮肤及鼻内芽生菌病感染：诊断困境
Cureus. 2018 Jan 21;10(1):e2095. doi: 10.7759/cureus.2095.
7
Infectious complications in patients on treatment with Ruxolitinib: case report and review of the literature.芦可替尼治疗患者的感染性并发症：病例报告及文献复习。
Infect Dis (Lond). 2018 May;50(5):381-387. doi: 10.1080/23744235.2017.1390248. Epub 2017 Dec 18.
8
Ruxolitinib-associated infections: A systematic review and meta-analysis.芦可替尼相关感染：系统评价和荟萃分析。
Am J Hematol. 2018 Mar;93(3):339-347. doi: 10.1002/ajh.24976. Epub 2017 Dec 4.
9
Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor.芦可替尼治疗骨髓纤维化：是否会成为一种免疫干扰剂。
Ther Clin Risk Manag. 2017 Feb 13;13:169-177. doi: 10.2147/TCRM.S121683. eCollection 2017.
10
Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?芦可替尼是一种强效免疫抑制化合物：是时候进行抗感染预防了吗？
Blood. 2013 Nov 28;122(23):3843-4. doi: 10.1182/blood-2013-10-531103.
Zotero 插件